For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Otsuka Applies for Mucosta Eye Drop for Dry Eye
November 29, 2010
- Rohto: Record-High Profits despite Flat Sales
November 29, 2010
- Otsuka Applies for Levocarnitine Based on Published Evidence
November 29, 2010
- GSK to Launch Switch OTC Steroidal Agent
November 29, 2010
- Nippon Kayaku Applies for LCH for Exal Based on Data from Public Domain
November 29, 2010
- Oral Ketotifen Products Should Remain in Class 1: JPA
November 29, 2010
- Bristol-Myers Required to Develop Largest Number of Unapproved Drugs/Indications
November 29, 2010
- 64 Amaryl Generics from 28 Companies Listed
November 29, 2010
- Better Understanding of Etiology Essential to Develop Effective Anti-AD Drugs: Dr Iwai of Astellas
November 29, 2010
- New Premiums for Dispensing Generics Boost Sales of Top-4 Generic Makers
November 29, 2010
- Indacaterol as Effective as Tiotropium: Novartis
November 29, 2010
- Takara Bio: Sales Down 2.9%, Instrument Business in Slump
November 29, 2010
- Sawai: Strong Sales to Pharmacies Boost Sales, Profits
November 29, 2010
- Eisai Enters into Research Collaboration with FORMA
November 29, 2010
- Sales, Profits Up for 3 Leading Dispensing Pharmacy Chains
November 29, 2010
- Taiyo: Profits Down Due to Business Suspension
November 29, 2010
- Sekisui Chemical Acquires Diagnostics Business from Genzyme
November 29, 2010
- 42 National Univ. Hospitals to Investigate Mutual Drug Purchase Prices
November 29, 2010
- Towa: Sales, Profits Outperform Forecasts
November 29, 2010
- Miraca HD: Acquisition Drives Sales, Up 9.9%
November 29, 2010
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…